BioPharmSignal logoBioPharmSignal

Biotech News

Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026

Geron (GERN)GeronCompany update

New analyses further characterize the clinical activity and approved dosing regimen of RYTELO® (imetelstat) in lower-risk MDS New analyses further characterize the clinical activity and approved dosing regimen of RYTELO® (imetelstat) in lower-risk MDS

Related news

GERNGeron2026-10-28 12:00 EST

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

KURAKura Oncology2026-11-04 14:02 EST

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

TEVATeva Pharmaceutical Industries2026-10-02 12:00 EST

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

IMTXImmatics2026-10-24 06:30 EST

Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting

LYELLyell Immunopharma2026-11-04 14:01 EST

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

KPTIKaryopharm Therapeutics2026-11-04 14:01 EST

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

LEGNLegend Biotech Corporation2026-11-04 14:00 EST

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

CHRSCoherus BioSciences, Inc.2026-10-28 20:05 EST

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

View all latest news

Geron

Telomerase-Targeted Hematology Company Geron is a commercial-stage biopharmaceutical company focused on blood cancers. Its scientific and commercial strategy is built around inhibiting telomerase, an enzyme involved in the continued proliferation of malignant cells. RYTELO in Lower-Risk MDS RYTELO, or imetelstat, is a first-in-class...

Recent company news

GERNGeron2026-11-04 14:00 EST

Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

GERNGeron2026-10-28 12:00 EST

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

GERNGeron2026-10-19 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.95 USD
Market cap
750.58M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States